Synthego has launched a genome engineering service for induced pluripotent stem (iPS) cells, an expansion of automated cell editing capabilities that is designed to achieve extremely high editing efficiency of iPS cells at an industrial scale, and address the dearth of high-quality, physiologically relevant biological models needed for translational medicine . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge